The next Virtual BPF Seminar, "Peptide Design: The Innies and Outies of Cellular Targeting", will be held Tuesday, June 3rd starting at 12:00 PM EDT (9:00 AM PDT). Join us for this webinar where science meets the surreal world of Severance! Just like the employees of Lumon Industries, we can design peptides to have dual roles, targeting both the "innies" (inside the cells) and the "outies" (outside the cells).

We will explore the fascinating realm of peptide design, where these molecular workers can be engineered to penetrate cells, ensuring they perform their duties with selective targeting unique to peptides. But that's not all—peptides can be designed to also have a mission outside the cells, navigating the extracellular environment to find and bind to specific cell types, delivering their therapeutic payloads.

In this panel discussion, we welcome two peptide enthusiasts to discuss their approach to and the future of peptide design. Tony Silvestri of Unnatural Products will discuss how his team approaches macrocycle drug design to optimize cellular penetration. We will also be joined by Andre Watson of Ligandal who harnesses the unique binding specificity of peptides to optimize nanoparticle drug delivery.

Join us for an engaging discussion and gain valuable insights into peptide design. Unlike the employees of Lumon Industries, you'll leave with your memory not only intact but enriched with new ideas on how peptides can be leveraged in drug development!

Registration is free and can be completed at Virtual BPS | Boulder Peptide Symposium. *Note* you must be signed in to the site in order to sign up.

These educational e-seminars are provided free of charge by the Boulder Peptide Foundation. If your company is interested in supporting this or other educational initiatives, please email sponsorship@boulderpeptide.org.

The next Virtual BPF Seminar, "Discovering Therapeutic Applications of Snail Venom Peptides", will be held Wednesday, November 13th starting at 12:00 PM EST (9:00 AM PST). We will be hosting Dr. Mandë Holford (Professor, Hunter College - CUNY) and Dr. Walden Bjørn-Yoshimoto (Assistant Professor, University of Copenhagen). Each will present their work exploring therapeutic applications for snail venom peptides. A moderated Q&A session will follow each presentation.

Registration is free, and can be completed at Virtual BPS | Boulder Peptide Symposium. *Note* you must be signed in to the site in order to sign up.

These educational e-seminars are provided free of charge by the Boulder Peptide Foundation. If your company is interested in supporting this or other educational initiatives, please email sponsorship@boulderpeptide.org.

The next Virtual BPF Seminar, "Strategies of Detection and Mitigation of Immunogenicity from Peptide Therapeutics", will be held Wednesday, May 22nd starting at 1:00 PM EDT (10:00 AM PDT). We will be hosting Dr. Daniela Verthelyi (Chief of the Immunology Lab in the Office of Pharmaceutical Quality Research at CDER and FDA) and Dr. Brian Roberts (Director of Preclinical Immunology at EpiVax, Inc) who will each present their work on strategies they are using to detect and mitigate immunogenicity response from peptide therapeutics and related impurities. A moderated panel discussion and Q&A session will follow each presentation.

Registration is free, and can be completed at Virtual BPS | Boulder Peptide Symposium. *Note* you must be signed in to the site in order to sign up.

These educational e-seminars are provided free of charge by the Boulder Peptide Foundation. If your company is interested in supporting this or other educational initiatives, please email sponsorship@boulderpeptide.org.

The Meienhofer Award was established in 2007 to recognize an individual with a lifetime of achievement in peptide science. The biennial award is named after Johannes Meienhofer, in honor of his transformative discoveries in solid phase peptide synthesis. Notably, Meienhofer's work demonstrated the power of medicinal chemistry in peptide pharmacology and is considered to have laid the foundation of modern synthetic peptide therapeutics.

Dr. Fernando Albericio, recipient of the 2024 Meienhofer Award, began his peptide journey almost 50 years ago in his native Barcelona. He earned his Ph.D. in Chemistry at the University of Barcelona (UB) under the guidance of Ernest Giralt. After several postdoctoral stays at Tufts University (Victor Najjar); Université d’Aix-Marseille (Jurphass van Rietschoten); and University of Minnesota (George Barany) he returned to Barcelona in 1985 as an Associate Professor at the UB. From 1992-94, he was Director of Peptide Research at Millipore in Boston. He rejoined the UB after this period and was promoted to Full Professor in 1995. From 2003-2015, he was Group Leader at the Institute for Research in Biomedicine (IRB). From 2014-2015, he was founder Rector of Yachay Tech, a university in Ecuador. Currently, he is a Research Professor at the University of KwaZulu-Natal (South Africa) and an Emeritus Professor of Organic Chemistry at the University of Barcelona (Spain).

His primary research interests cover practically all aspects of peptide synthetic methodology; the synthesis of peptides and small molecules with therapeutic activities (cancer and infectious diseases); and peptide-based drug delivery systems.   Most recently, he has been working on greening solid-phase peptide synthesis processes. He has published over 1000 scientific articles and graduated more than 75 Ph.D. students.

Fernando has received several awards, including the Vincent du Vigneaud and the Murray Goodman Awards from the American Peptide Society, and the Leonidas Zervas from the European Peptide Society.

Dr. Albericio will receive his award Tuesday, September 17th during the 2024 Boulder Peptide Symposium. Register today!

More information on the Meienhofer Award, including a list of previous recipients, and the Boulder Peptide Symposium can be found online at www.boulderpeptide.org/meienhofer-award.